Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression
Oncology Research · 2025 · 33 (3) · 567-575
DOI: 10.32604/or.2024.051672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Baoxing Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, China. Hauptthemen laut MEDLINE: Lipocalin-2, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Lipocalin-2 (LCN2) is a member of the lipocalin superfamily with multiple functions and can participate in the transport of a variety of small lipophilic ligands in vivo. LCN2 is significantly expressed in various tumors and plays an important role in regulating tumor cell proliferation, invasion, and metastasis. The specific actions of LCN2 in tumors may vary depending on the particular type of cancer involved. In this review, we provide an extensive overview of the transcriptional and post-transcriptional regulation of LCN2 in health and disease. Furthermore, we summarize the impact of LCN2 dysregulation in a broad range of tumors. Lastly, we examine the mechanisms of action of LCN2 during tumorigenesis, progression, and metastasis. Understanding the complex relationships between LCN2 and tumor development, progression, and metastasis is vital for advancing our knowledge of cancer biology, developing biomarkers for diagnosis and clinical decision-making, and creating therapeutic strategies to improve the management of patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, China.
- State Key Laboratory of Tree Genetics and Breeding, Co-Innovation Center for Sustainable Forestry in Southern China, Key Laboratory of Tree Genetics and Biotechnology of Educational Department of China, Key Laboratory o…
- Department of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Zitieren
APA
Huang, B., Jia, Z., Fu, C., Chen, M., Su, Z., & Chen, Y. (2025). Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression. Oncology Research, 33(3), 567-575. https://doi.org/10.32604/or.2024.051672
Vancouver
Huang B, Jia Z, Fu C, Chen M, Su Z, Chen Y. Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression. Oncology Research. 2025;33(3):567-575. doi:10.32604/or.2024.051672
BibTeX
@article{Huang2025,
author = {Huang, Baoxing and Jia, Zichang and Fu, Chenchen and Chen, Moxian and Su, Zezhuo and Chen, Yunsheng},
title = {Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression},
journal = {Oncology Research},
year = {2025},
volume = {33},
number = {3},
pages = {567--575},
doi = {10.32604/or.2024.051672}
}
EUVIMED